BD Announces Agreement to Acquire HandyLab, Inc.

Featured In: Supplier News

By Becton, Dickinson and Company Thursday, October 29, 2024

Loading...
(October 23, 2024) -- BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it signed a definitive agreement to acquire HandyLab, Inc., an Ann Arbor, Michigan-based company that develops and manufactures molecular diagnostic assays and automation platforms. The acquisition is subject to regulatory approvals and is expected to close during the first quarter of fiscal year 2010. The financial terms of the agreement were not disclosed.

Consistent with BDs stated acquisition strategy, and building upon a previously announced development and distribution agreement between BD and HandyLab earlier in 2009, the acquisition would further extend BDs commitment to the novel HandyLab instrumentation technology to support BDs molecular diagnostics strategy.

HandyLab has developed and commercialized a flexible automated platform for performing molecular diagnostics which is an ideal complement to our molecular diagnostics offerings, said Vincent A. Forlenza, BD President. We believe this new platform enables both our healthcare-associated infections offering and future expansion into other molecular opportunities.

BD plans to place its BD GeneOhm" molecular assays for Methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile and Vancomycin-resistant Enterococcus (VRE) onto the HandyLab platform and market them as the new BD MAX" system. The flexibility of this novel platform will allow further expansion of the BD molecular diagnostic menu. BD senior management will address this announcement during the Companys fiscal fourth quarter earnings call on November 4, 2009, which will be broadcast live on BD's website, www.bd.com/investors, at 10:00 a.m. (ET).

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com

***
This press release contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding the acquisition of HandyLab, Inc., the timing of the anticipated acquisition, the potential benefits of the anticipated acquisition and the potential benefits of the products and product candidates relating to the HandyLab instrumentation technology and events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to:  the satisfaction of closing conditions with respect to the acquisition; the ability to successfully integrate HandyLabs operations and programs with BDs and the time and resources required to do so; difficulties inherent in product development and delays in product introductions; competitive factors; pricing and market share pressures; increases in energy costs and their effect on, among other things, the cost of producing BDs products; fluctuations in costs and availability of raw materials and in BDs ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation (as described in BDs filings with the Securities and Exchange Commission); the effects of potential pandemic diseases; changes in healthcare or other governmental regulation, including changes in government pricing and reimbursement policies or other cost containment reforms; and issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BDs filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

SOURCE

Join the Discussion
Rate Article: Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

Research Exchange

Meeting the Challenges of Long-term Time-lapse Imaging

Oct 26

Recent technological developments in the sequence capture of cellular events through a light microscope can be combined to image multiple independent experiments automatically, with many advantages.

Handle With Care

Aug 26

Researchers face the dual challenges of difficult to handle and hard to maintain stem cells.

Six Tips for More Successful Cell Cultures

Aug 18

For those who perform cell culture experiments, it pays to be meticulous. Even seemingly minor handling techniques and lab equipment features can make a difference in achieving success.

Rapid Generation of Assay-ready Serial Dilution Plates Using Two-stage Low Volume Pipetting

Jul 22

Researchers see the benefits of streamlining accurate serial dilution of stock solutions of compounds. By Joby Jenkins, TTP LabTech As the cost of drug development escalates there is a growing requirement to accelerate the R&D cycle and eliminate unwanted off-target drug effects earlier.

The Future of the FDA: Operating in an Electronic World

Oct 12

Acording to an Axendia reseach study, the FDA is currently shifting its organizational and technology infrastructures to facilitate electronic interactions with the companies it regulates.

Tissue Microarrays - Opening up new opportunities in the Therapeutics sector

Oct 12

Tissue Microarray has become a pivotal cog in the wheel for high throughput studies and is an integral part in the validation process for screening results from discovery platforms for expression studies using various approaches.

Translational Informatics for Systems Biology

Oct 12

A study in which IO Informatics' Sentient software has been applied to integrating and linking a customer's multiple data streams.

De Novo Formula Generation with Sub-ppm Confidence

Oct 12

Novel technology embodied in the micrOTOF allows precise measurement of both accurate mass and True Isotopic Pattern (TIP) over a wide dynamic range, allowing for the implementation of an open access system.

ADP-Glo™: An Ideal Approach to Monitor the Activity of Protein Kinases and Beyond

Oct 16

Because of its versatility (alltypesofsubstrates), robustness (Z’>0.8), rapidperformance, and its ease of use, the luminescence based Kinase Glo® assay platform has gained wide acceptance in many drug screening programs for protein kinase inhibitors.

A Cell-Based, Microplate Format, DELFIA Assay for Determination of the Activation of MAP KinaseSofia

Oct 16

Mitogen-activated protein kinases(MAPK) are activated in response to extracellularsignals or cellular stress. We have set up a cell-based DELFIA®Time-Resolved Fluorescence assay to test compounds or conditions for their ability to modulate cellular stress by the activation of MAPK.

Cell Based Assays for Studying the Effects of Cytotoxic Agents

Oct 16

Apoptosis, DNA fragmentation and cell proliferation are important parameters when studying live cell function, especially, when the effects of cytotoxic agents are under study.

A glimpse of canaan, 40 years on. The Johann jacob wepfer award 2009.

1 hour ago

During the last few decades an explosion in definitions has occurred covering brief to permanent focal syndromes, diagnostic categories for stroke and subtypes, scoring systems characterizing clinical syndromes as well as imaging, and fostered the ascendancy of biostatistics...

Cognitive decline and mortality in a community-based cohort: the Monongahela Valley Independent Elders Survey.

3 hours ago

OBJECTIVES: To compare, in a longitudinal cohort study, declines in specific cognitive domains on their ability to predict time to death, in the presence and absence of dementia, and to explore an explanatory role for vascular disease. DESIGN: Prospective population-based...

Ultrafine carbon particles down-regulate CYP1B1 expression in human monocytes.

3 hours ago

ABSTRACT: BACKGROUND: Cytochrome P450 monoxygenases play an important role in the defence against inhaled toxic compounds and in metabolizing a wide range of xenobiotics and environmental contaminants. In ambient aerosol the ultrafine particle fraction which penetrates deeply...

The impact of habitat fragmentation on tsetse abundance on the plateau of eastern Zambia.

3 hours ago

Tsetse-transmitted human or livestock trypanosomiasis is one of the major constraints to rural development in sub-Saharan Africa. The epidemiology of the disease is determined largely by tsetse fly density. A major factor, contributing to tsetse population density is the...

Request for Entries

Oct 16

Ask the Experts is your chance to get the answers to questions on applications, materials, methods, processes, and technologies. Email you question to bst_web@advantagemedia.com, and the editors of Bioscience Technology will find an appropriate expert to answer it. Watch this space in the future to see the questions your colleagues are posting.

STAY INFORMED: SUBSCRIBE TO

Magazine and E-mail Newsletters

Loading...
E-mail:   

MULTIMEDIA

Video:

Frontiers in Bioscience Learning and Memory Video

Oct 6

How does the brain learn and remember? An academic conference "Frontiers in Bioscience Learning and Memory" was held at City University of Hong Kong on June 16th.

Podcasts:

Allen Institute for Brain Research

Allen Institute for Brain Research

Oct 14

Discussed in this interview are both the mouse brain project and the human cortex project with an emphasis on the importance of these projects to neuroscience research.